Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Laurus Labs, a leading research-driven pharmaceutical company from India, focuses on developing and manufacturing Active Pharmaceutical Ingredients (APIs), generic formulations, and contract research and manufacturing (CRO/CMO) services. With a specialization in innovative therapies for HIV/AIDS, Hepatitis C, and cancer, Laurus Labs delivers high-quality pharmaceutical solutions globally, underscoring its commitment to advancing healthcare.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Laurus Labs is scheduled to report its next quarterly earnings on 10/22/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Laurus Labs last reported quarterly earnings on 7/24/2026 (Q2 2026). Earnings per share (EPS) came in at 6.80 INR.
Across its last 5 earnings reports, Laurus Labs stock moved by ±1.6% on average the following day. The largest reaction was +3% on 01/24/2025; 4 of 5 reactions were positive.
Laurus Labs has beaten analyst EPS estimates in 4 of its last 4 evaluated quarters (beat rate: 100%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 4 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.